Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series

Abstract Background The Coronavirus disease 2019 (COVID-19) caused by the new Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has become a pandemic, affecting the therapeutic management for Multiple Sclerosis (MS). Any decision regarding the discontinuation of high-potency agents for mo...

Full description

Saved in:
Bibliographic Details
Main Authors: Clara G. Chisari, Simona Toscano, Sebastiano Arena, Chiara Finocchiaro, Arturo Montineri, Francesco Patti
Format: article
Language:EN
Published: BMC 2021
Subjects:
Online Access:https://doaj.org/article/0bf582194b9040e3bc74df823d15f075
Tags: Add Tag
No Tags, Be the first to tag this record!